Cutting the costs of migraine: Role of the employee health unit

Journal of Occupational and Environmental Medicine

Volumn 40, Issue 11, 1998, Pages 943-953

  Warshaw, Leon J ^a,c   Burton, Wayne N ^b  

^a NEW YORK UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST CONTROL; EDUCATION PROGRAM; EMPLOYEE; FUNCTIONAL ASSESSMENT; HEADACHE; HEALTH CARE COST; HUMAN; JOB PERFORMANCE; MIGRAINE; PREVALENCE; QUALITY OF LIFE;

EID: 0031726190     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-199811000-00002     Document Type: Article

References (62)

1. Lipton RB, Stewart WF, Von Korff M. Burden of migraine, societal costs and therapeutic opportunities. Neurology. 1997;48(suppl 3):S24-S29.
2. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994;34: 337-343.
3. De Lissovy G, Lazarus SS. The economic cost of migraine: present state of knowledge. Neurology. 1994;44(suppl 4):S56-S62.
4. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother. 1994;28:659-664.
5. Osterhaus J, Gutterman DI, Plachetka JR. Healthcare resource and lost labor costs of migraine headaches in the United States. PharmacoEconomics. 1992;2:67-76.
6. Centers for Disease Control and Prevention. Prevalence of migraine headache, United States, 1980-1989. MMWR. 1991;40:331-333.
7. Stang PE, Yanigihara T, Swanson JW, et al. Incidence of migraine headache: a population-based study in Olmstead County, Minnesota. Neurology. 1992;42: 1657-1662.
8. Sillinpaa M. Headache in children. In: Olesen J, ed. Headache Classification and Epidemiology. New York: Raven Press; 1994:273-281.
9. Stang PE, Osterhaus JT, Celentano DD. Migraine: patterns of health care use. Neurology. 1995;44(suppl 4):S47-S55.
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7): 1-96.
11. Couch JR, Bearrs CM. Relief of migraine headache with sexual orgasm. Headache. 1987;27:287.
12. Galiano L, Monteil I, Falip R, Asensio M, Matias-Guiu J. Stress as a precipitating factor in migraine. Rev Neurol. 1995; 23:830-832.
13. Robbins S. Precipitating factors in migraine: a retrospective review of 494 patients. Headache. 1994;34:214-216.
14. Antonov K, Isacson D. Headache in Sweden: the importance of working conditions. Headache. 1997;37:228-234.
15. Spierings EL, Sorbi M, Haimowitz BR, Tellegen B. Changes in daily hassles, mood and sleep in the 2 days before a migraine headache. Clin J Pain. 1996;12: 38-42.
16. Silberstein SD, Lipton RB. Overview of the diagnosis and treatment of migraine. Neurology. 1994;44(suppl 7):S6-S16.
17. Merikangas KR, Dartigues JF, Whittaker A, Angst J. Diagnostic criteria for migraine: a validity study. Neurology. 1994; 44(suppl 4):S11-S18.
18. Silberstein SD. Advances in understanding the pathophysiology of migraine. Neurology. 1992;43(suppl 2):S6-S10.
19. Stewart WF, Staffa J, Lipton RB, Ottman R. Familial risk of migraine: a population-based study. Ann Neurol. 1997;41: 166-172.
20. Peroutka SJ. Genetic evaluation of migraine. In: Goadsby PJ, Silberstein SD, eds. Headache. Boston: Butterworth-Heinemann; 1997:107-114.
21. Silberstein SD. Advances in the pathophysiology of headache. Neurology. 1993;42(suppl 2):S6-S10.
22. Lance JW. Current concepts of migraine pathogenesis. Neurology. 1993;43(suppl 3):S11-S15.
23. Martin GR. Serotonin receptor involvement in the pathogenesis and treatment of migraine. In: Goadsby PJ, Silberstein SD, eds. Headache. Boston: Butterworth-Heinemann; 1997:39-58.
24. Stewart WF, Schlechter A, Rasmussen BK. Migraine prevalence: a review of population-based studies. Neurology. 1994;44(suppl 4):S17-S23.
25. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993; 43(suppl 3):S6-S10.
26. Warshaw LJ, Lipton RB, Silberstein SD. Migraine: a "woman's disease?" Women Health. In press.
27. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Neurology. In press.
28. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: a national probability sample survey. Neurology. 1992;42: 223-228.
29. Lipton RB, Amatniek JC, Ferrari MD, Gross M. Migraine. Identifying and removing barriers to care. Neurology. 1994;44(suppl 4):S63-S68.
30. Siegler DK. The treatment of migraine. In: Dalessio DJ, ed. Wolff's Headache and Other Head Pain, 5th ed. New York: Oxford University Press; 1987:87-111.
31. Adelman JU, Von Seggern R. Cost considerations in headache therapy. Part I: Prophylactic migraine treatment. Headache. 1995;35:479-487.
32. Tfelt-Hansen P, Johnson ES. Nonsteroidal anti-inflammatory drugs in the treatment of the acute migraine attack. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press Ltd; 1993:305-311.
33. Volans GN. The effects of metaclopramide on the absorption of effervescent aspirin in migraine. Br J Pharmacol. 1975;2:57-63.
34. Mathew NT. Migraine transformation and chronic daily headache. In: Cady RK, Fox AW, eds. Treating the Headache Patient. New York: Marcel Dekker; 1994:75-100.
35. The Multinational Oral Sumatriptan and Cafergot International Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol. 1991; 31:314-322.
36. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
37. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-321.
38. Sorbi M, Telegen B, du Long A. Long-term effect of training in relaxation and stress coping in patients with migraine: a 3-year followup. Headache. 1989;29: 111-121.
39. McGrath PJ, Sorbi M. Psychological treatments. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press Ltd; 1993:289-294.
40. Tfelt-Hansen P. Prophylactic pharmacotherapy of migraine: Some practical guidelines. Neurol Clin. 1997;15:153-165.
41. Newman LC, Lipton RB, Lay CL, Solomon S. An open-label pilot study of oral sumatriptan in the intermittent prophylaxis of menstrual migraine. Cephalalgia. 1997;17:437-438.
42. Herzog AG. Continuous bromocriptine therapy in menstrual migraine. Neurology. 1997;48:101-102.
43. Tfelt-Hansen P, Welch KMA. Prioritizing prophylactic treatment. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press, Ltd: 1993:299-303.
44. Schwartz BS, Schechter A, Lipton RB. Migraine heterogenicity: disability, pain intensity, and attack frequency and duration. Neurology. 1994;44(suppl 4):24-39.
45. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on clinical, epidemiological and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19:333-339.
46. Clarke CE, MacMillan L, Sondhi S, Wells NEJ. Economic and social impact of migraine. Q J Med. 1996;89:77-84.
47. Dartigues MP, Lindouisi JF, Henry A. Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache. 1997;37:71-78.
48. Micieli G, Frediani F, Cavalini A, Rossi F, Bussone G, Merli S, Nappi G. Quantification of headache disability: a diagnostic-based approach. Headache. 1995; 35:131-137.
49. Mounstephen AH, Harrison RK. A study of migraine and its effects in a working population. Occup Med. 1995:45:311-317.
50. Blau JN. Migraine in doctors: work loss and consumption of medication. Lancet. 1994;344:1623-1624.
51. Burton WN, Hoy DA, Stevens M. A computer-assisted health care management system. J Occup Med. 1991;33: 268-271.
52. Schneider WJ, Furth PJ, Blalock TH, Sherrill TA. A pilot study of a headache program in the workplace: the effects of education. J Occup Environ Med. In press.
53. Warshaw LJ. Health risk appraisal. In: Stellman JM, ed. Encyclopaedia of Occupational Health and Safety, 4th ed. Geneva: International Labour Organization; 1998;1:15.24-15.28.
54. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an autoinjector device. Eur Neurol. 1991;31: 323-331.
55. Legg RF, Sclar DA, Nemec NL, Tarnal J, Mackowiak JI. Cost benefit of sumatriptan to the employer. J Occup Environ Med. 1997;39:652-657.
56. Warshaw LJ, Burton WN, Silberstein SD, Lipton RB. Migraine: a problem for employers and managed care plans. Am J Managed Care. 1997;3:1515-1523.
57. Cady RC, Ryan R, Jhingran P, O'Quinn S. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med. 1998;158: 1013-1018.
58. Mushet GR, Miller DW, Clements B, Pait G, Gutterman DL. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees. Headache. 1996;36:137-143.
59. Adelman JR, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on work-place productivity, health related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Managed Care. 1996;2: 1245-1254.
60. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment of migraine. J Fam Pract. 1996;42:36-42.
61. Mencken M. Commentary on "Intranasal lidocaine relieved acute migraine pain." ACP Journal Club. 1997:126:17. Comment on: Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for the treatment of migraine: a randomized double-blind controlled trial. JAMA. 1996; 276:313-32.
62. Mencken M. Commentary on "Intranasal lidocaine relieved acute migraine pain." ACP Journal Club. 1997:126:17. Comment on: Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for the treatment of migraine: a randomized double-blind controlled trial. JAMA. 1996; 276:313-32.